Erratum: Isoquercitrin inhibits the progression of liver cancer in vivo and in vitro via the MAPK signalling pathway (Oncology Reports (2014) 31 (2377-2384) Doi: 10.3892/or.2014.3099);Isoquercitrin inhibits the progression of liver cancer in vivo and in vitro via the MAPK signalling pathway

Oncology Reports

Volumn 31, Issue 5, 2014, Pages 2377-2384

  Huang, Guihong ^a   Tang, Bo ^a   Tang, Kun ^a   Dong, Xiaomin ^a   Deng, Jungang ^a   Liao, Luqin ^a   Liao, Zengzhen ^a   Yang, Hua ^a   He, Songqing ^a  

^a GUILIN MEDICAL UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Isoquercitrin; Progression

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; ISOQUERCITRIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE C; STRESS ACTIVATED PROTEIN KINASE; QUERCETIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG INHIBITION; DRUG STRUCTURE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER; MALE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; CHINESE MEDICINE; DISEASE COURSE; DRUG EFFECTS; DRUG SCREENING; G1 PHASE CELL CYCLE CHECKPOINT; HEPG2 CELL LINE; LIVER NEOPLASMS; METABOLISM; NUDE MOUSE; PHOSPHORYLATION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CASPASE 3; CASPASE 8; CASPASE 9; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; G1 PHASE CELL CYCLE CHECKPOINTS; HEP G2 CELLS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIVER NEOPLASMS; MALE; MAP KINASE SIGNALING SYSTEM; MEDICINE, CHINESE TRADITIONAL; MICE; MICE, NUDE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; QUERCETIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84898650544     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2023.8510     Document Type: Erratum

References (40)

1. van Meer S, de Man RA, Siersema PD and van Erpecum KJ: Surveillance for hepatocellular carcinoma in chronic liver disease: Evidence and controversies. World J Gastroenterol 19: 6744-6756, 2013
2. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005
3. Liu Y, Chang CC, Marsh GM and Wu F: Population attributable risk of aflatoxin-related liver cancer: Systematic review and meta-analysis. Eur J Cancer 48: 2125-2136, 2012
4. Li M, Qiao C, Qin L, Zhang J and Ling C: Application of traditional Chinese medicine injection in treatment of primary liver cancer: A review. J Tradit Chin Med 32: 299-307, 2012
5. Maluccio M and Covey A: Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin 62: 394-399, 2012
6. Belghiti J and Fuks D: Liver resection and transplantation in hepatocellular carcinoma. Liver Cancer 1: 71-82, 2012
7. Eguchi S, Kanematsu T, Arii S, Omata M, Kudo M, Sakamoto M, Takayasu K, Makuuchi M, Matsuyama Y, Monden M; Liver Cancer Study Group of Japan: Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma. Br J Surg 98: 552-557, 2011
8. Huang J, Yan L, Cheng Z, Wu H, Du L, Wang J, Xu Y and Zeng Y: A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg 252: 903-912, 2010
9. Wang W, Shi J and Xie WF: Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: A meta-analysis. Liver Int 30: 741-749, 2010
10. Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, Yu D, Meyer T, Patch DW and Burroughs AK: Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev 32: 594-606, 2006
11. Roomi MW, Roomi NW, Kalinovsky T, Niedzwiecki A and Rath M: Micronutrient synergy in the fight against hepatocellular carcinoma. Cancers 4: 323-339, 2012
12. Ghosh A, Ghosh D, Sarkar S, Mandal AK, Thakur Choudhury S and Das N: Anticarcinogenic activity of nanoencapsulated quercetin in combating diethylnitrosamine-induced hepatocarcinoma in rats. Eur J Cancer Prev 21: 32-41, 2012
13. Khan MS, Halagowder D and Devaraj SN: Methylated chrysin induces co-ordinated attenuation of the canonical Wnt and NF-kB signaling pathway and upregulates apoptotic gene expression in the early hepatocarcinogenesis rat model. Chem Biol Interact 193: 12-21, 2011
14. Liu H, Dong A, Gao C, Tan C, Xie Z, Zu X, Qu L and Jiang Y: New synthetic flavone derivatives induce apoptosis of hepatocarcinoma cells. Bioorg Med Chem 18: 6322-6328, 2010
15. Ullmannova V and Popescu NC: Inhibition of cell proliferation, induction of apoptosis, reactivation of DLC1, and modulation of other gene expression by dietary flavone in breast cancer cell lines. Cancer Detect Prev 31: 110-118, 2007
16. Yang QH, Yang J, Liu GZ, Wang L, Zhu TC, Gao HL and Kou XG: Study on in vitro anti-tumor activity of Bidens bipinnata L. extract. Afr J Tradit Complement Altern Med 10: 543-549, 2013
17. Wu J, Wan Z, Yi J, Wu Y, Peng W and Wu J: Investigation of the extracts from Bidens pilosa Linn. var. radiata Sch. Bip. for antioxidant activities and cytotoxicity against human tumor cells. J Nat Med 67: 17-26, 2013
18. Kumari P, Misra K, Sisodia BS, Faridi U, Srivastava S, Luqman S, Darokar MP, Negi AS, Gupta MM, Singh SC and Kumar JK: A promising anticancer and antimalarial component from the leaves of Bidens pilosa. Planta Med 75: 59-61, 2009
19. Kviecinski MR, Felipe KB, Schoenfelder T, de Lemos Wiese LP, Rossi MH, Gonçalez E, Felicio JD, Filho DW and Pedrosa RC: Study of the antitumor potential of Bidens pilosa (Asteraceae) used in Brazilian folk medicine. J Ethnopharmacol 117: 69-75, 2008
20. Ong PL, Weng BC, Lu FJ, Lin ML, Chang TT, Hung RP and Chen CH: The anticancer effect of protein-extract from Bidens alba in human colorectal carcinoma SW480 cells via the reactive oxidative species- and glutathione depletion-dependent apoptosis. Food Chem Toxicol 46: 1535-1547, 2008
21. Ma TT, Xie J, Zhang QL, Xu H, Li J and Chen FH: Analysis of fingerprint and bioactive components of Bidens biternata by HPLC. Zhong Yao Cai 35: 892-896, 2012 (In Chinese)
22. Zhong MM, Chen FH, Yuan LP, Wang XH and Wu FR: Study on the property of adsorption and separation of the macroporous resins for total flavonoids of Bidens bipinnata L. Zhong Yao Cai 30: 338-341, 2007 (In Chinese)
23. Zhong MM, Chen FH, Yuan LP, Wang XH, Wu FR, Yuan FL and Cheng WM: Protective effect of total flavonoids from Bidens bipinnata L. against carbon tetrachloride-induced liver injury in mice. J Pharm Pharmacol 59: 1017-1025, 2007
24. Yuan LP, Chen FH, Ling L, Bo H, Chen ZW, Li F, Zhong MM and Xia LJ: Protective effects of total flavonoids of Bidens bipinnata L. against carbon tetrachloride-induced liver fibrosis in rats. J Pharm Pharmacol 60: 1393-1402, 2008
25. Fabregat I, Roncero C and Fernández M: Survival and apoptosis: A dysregulated balance in liver cancer. Liver Int 27: 155-162, 2007
26. Koschny R, Brost S, Hinz U, Sykora J, Batke EM, Singer S, Breuhahn K, Stremmel W, Walczak H, Schemmer P, Schirmacher P and Ganten TM: Cytosolic and nuclear caspase-8 have opposite impact on survival after liver resection for hepatocellular carcinoma. BMC Cancer 13: 532, 2013
27. Kumar S and Vaux DL: Apoptosis. A cinderella caspase takes center stage. Science 297: 1290-1291, 2002
28. Dewson G and Kluck RM: Mechanisms by which Bak and Bax permeabilise mitochondria during apoptosis. J Cell Sci 122: 2801-2808, 2009
29. Fombonne J, Bissey PA, Guix C, Sadoul R, Thibert C and Mehlen P: Patched dependence receptor triggers apoptosis through ubiquitination of caspase-9. Proc Natl Acad Sci USA 109: 10510-10515, 2012
30. Rew DA and Wilson GD: Cell production rates in human tissues and tumours and their significance. Part II: Clinical data. Eur J Surg Oncol 26: 405-417, 2000
31. Kazi A and Dou QP: Cell cycle and drug sensitivity. Methods Mol Med 111: 33-42, 2005
32. Fecher LA, Amaravadi RK and Flaherty KT: The MAPK pathway in melanoma. Curr Opin Oncol 20: 183-189, 2008
33. Junttila MR, Li SP and Westermarck J: Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J 22: 954-965, 2008
34. Roberts PJ and Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291-3310, 2007
35. Kohno M and Pouyssegur J: Targeting the ERK signaling pathway in cancer therapy. Ann Med 38: 200-211, 2006
36. Das M, Garlick DS, Greiner DL and Davis RJ: The role of JNK in the development of hepatocellular carcinoma. Genes Dev 25: 634-645, 2011
37. Dhanasekaran DN and Reddy EP: JNK signaling in apoptosis. Oncogene 27: 6245-6251, 2008
38. Nateri AS, Spencer-Dene B and Behrens A: Interaction of phosphorylated c-Jun with TCF4 regulates intestinal cancer development. Nature 437: 281-285, 2005
39. Marengo B, De Ciucis CG, Ricciarelli R, Furfaro AL, Colla R, Canepa E, Traverso N, Marinari UM, Pronzato MA and Domenicotti C: P38MAPK inhibition: A new combined approach to reduce neuroblastoma resistance under etoposide treatment. Cell Death Dis 4: E589, 2013
40. Guo K, Liu Y, Zhou H, Dai Z, Zhang J, Sun R, Chen J, Sun Q, Lu W, Kang X and Chen P: Involvement of protein kinase C ?-extracellular signal-regulating kinase 1/2/p38 mitogen-activated protein kinase-heat shock protein 27 activation in hepatocellular carcinoma cell motility and invasion. Cancer Sci 99: 486-496, 2008